Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-05-13 4:05 pm Sale |
2024-05-09 | 13D | eFFECTOR Therapeutics, Inc. EFTR |
Carlyle Group Inc. CG |
193,195 4.100% |
-1 (-0.00%) |
Filing History |
| 2024-02-14 3:48 pm Purchase |
2023-12-31 | 13G | eFFECTOR Therapeutics, Inc. EFTR |
PFIZER INC PFE |
2,243,850 3.470% |
2,243,850 (New Position) |
Filing History |
| 2024-02-14 09:48 am Purchase |
2023-12-31 | 13G | eFFECTOR Therapeutics, Inc. EFTR |
SECTORAL ASSET MANAGEMENT INC | 2,382,644 3.700% |
2,287,338 (+2400.00%) |
Filing History |
| 2024-02-09 8:14 pm Sale |
2023-12-31 | 13G | eFFECTOR Therapeutics, Inc. EFTR |
SR ONE CAPITAL MANAGEMENT LLC | 0 0.000% |
-272,885 (Position Closed) |
Filing History |
| 2024-02-05 4:15 pm Purchase |
2023-12-31 | 13G | eFFECTOR Therapeutics, Inc. EFTR |
Altitude Life Science Ventures Fund II L.P. | 2,826,350 4.400% |
2,713,296 (+2400.00%) |
Filing History |
| 2023-11-22 4:16 pm Sale |
2023-11-15 | 13D | eFFECTOR Therapeutics, Inc. EFTR |
The Column Group II, LP | 0 0.000% |
-163,669 (Position Closed) |
Filing History |
| 2023-09-15 4:05 pm Sale |
2023-06-15 | 13D | eFFECTOR Therapeutics, Inc. EFTR |
The Column Group II, LP | 163,669 6.600% |
-8,704 (-5.05%) |
Filing History |
| 2023-08-18 4:16 pm Unchanged |
2023-08-08 | 13D | eFFECTOR Therapeutics, Inc. EFTR |
Carlyle Group Inc. CG |
193,196 7.800% |
0 (Unchanged) |
Filing History |
| 2023-03-07 5:25 pm Purchase |
2021-08-25 | 13G | eFFECTOR Therapeutics, Inc. EFTR |
Altitude Life Science Ventures Fund II L.P. | 113,054 6.700% |
113,054 (New Position) |
Filing History |
| 2023-02-14 06:33 am Unchanged |
2021-12-31 | 13G | eFFECTOR Therapeutics, Inc. EFTR |
Empyrean Capital Partners, LP | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2023-02-13 3:06 pm Sale |
2022-12-31 | 13G | eFFECTOR Therapeutics, Inc. EFTR |
SECTORAL ASSET MANAGEMENT INC | 95,306 5.700% |
-4 (-0.00%) |
Filing History |
| 2022-08-18 8:04 pm Purchase |
2022-05-10 | 13D | eFFECTOR Therapeutics, Inc. EFTR |
US VENTURE PARTNERS X LP | 179,223 10.800% |
179,223 (New Position) |
Filing History |
| 2022-08-18 7:54 pm Sale |
2022-08-09 | 13D | eFFECTOR Therapeutics, Inc. EFTR |
US VENTURE PARTNERS X LP | 0 0.000% |
-192,885 (Position Closed) |
Filing History |
| 2022-08-11 4:55 pm Purchase |
2022-08-01 | 13D | eFFECTOR Therapeutics, Inc. EFTR |
Carlyle Group Inc. CG |
193,196 11.700% |
193,196 (New Position) |
Filing History |
| 2022-02-14 4:04 pm Purchase |
2021-12-31 | 13G | eFFECTOR Therapeutics, Inc. EFTR |
PFIZER INC PFE |
89,754 5.560% |
89,754 (New Position) |
Filing History |
| 2022-02-11 8:35 pm Purchase |
2021-12-31 | 13G | eFFECTOR Therapeutics, Inc. EFTR |
SR ONE CAPITAL MANAGEMENT LLC | 272,885 16.900% |
272,885 (New Position) |
Filing History |
| 2022-02-11 6:32 pm Unchanged |
2021-12-31 | 13G | eFFECTOR Therapeutics, Inc. EFTR |
Beryl Capital Management LLC | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2022-02-11 09:18 am Purchase |
2021-12-31 | 13G | eFFECTOR Therapeutics, Inc. EFTR |
SECTORAL ASSET MANAGEMENT INC | 95,310 5.900% |
95,310 (New Position) |
Filing History |
| 2022-01-31 4:16 pm Unchanged |
2021-12-31 | 13G | eFFECTOR Therapeutics, Inc. EFTR |
Linden Capital L.P. | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2021-09-13 06:23 am Purchase |
2021-08-25 | 13D | eFFECTOR Therapeutics, Inc. EFTR |
US VENTURE PARTNERS X LP | 192,885 11.900% |
192,885 (New Position) |
Filing History |